Literature DB >> 17767919

Berberine-induced LDLR up-regulation involves JNK pathway.

Seahyoung Lee1, Hyun-Joung Lim, Jin-Hee Park, Kuy-Sook Lee, Yangsoo Jang, Hyun-Young Park.   

Abstract

Berberine, an herbal alkaloid, has been reported to have a lipid lowering effect by stabilizing hepatic LDLR mRNA in an ERK-dependent manner rather than promoting transcriptional activity. However, considering the complexity of interconnected signal pathways in biological processes, it is highly possible that there exist signal pathway(s) other than ERK pathway which contribute to the berberine-induced up-regulation of LDLR. In the present study, we examined possible involvement of other signal pathways in berberine-induced hepatic LDLR up-regulation. As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment. Furthermore, we demonstrate that putative c-jun binding site of LDLR promoter is important in berberine-induced LDLR transcription using luciferase assay. The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment. The present study demonstrates that berberine increases transcriptional activity of LDLR promoter and this involves JNK pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17767919     DOI: 10.1016/j.bbrc.2007.08.060

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease.

Authors:  Hui Dong; Fu-Er Lu; Li Zhao
Journal:  Chin J Integr Med       Date:  2012-02-05       Impact factor: 1.978

2.  Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice.

Authors:  Guoliang Cui; Xia Qin; Yuebo Zhang; Zhenwei Gong; Baoxue Ge; Ying Qin Zang
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

Review 3.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

4.  Modified methylenedioxyphenol analogs lower LDL cholesterol through induction of LDL receptor expression.

Authors:  Zhekang Ying; Rajagopal Desikan; Xiaohua Xu; Andrei Maiseyeu; Cuiqing Liu; Qinghua Sun; Ouiliana Ziouzenkova; Sampath Parthasarathy; Sanjay Rajagopalan
Journal:  J Lipid Res       Date:  2012-02-21       Impact factor: 5.922

5.  Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism.

Authors:  Qian Zhang; Xinhua Xiao; Kai Feng; Tong Wang; Wenhui Li; Tao Yuan; Xiaofang Sun; Qi Sun; Hongding Xiang; Heng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-26       Impact factor: 2.629

6.  Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia.

Authors:  Marco Gentile; Ilenia Calcaterra; Alfonso Strazzullo; Carmen Pagano; Delia Pacioni; Enza Speranza; Paolo Rubba; Gennaro Marotta
Journal:  Clin Lipidol       Date:  2015-11-23

Review 7.  Traditional chinese medicine in treatment of metabolic syndrome.

Authors:  Jun Yin; Hanjie Zhang; Jianping Ye
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-06       Impact factor: 2.895

8.  Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion.

Authors:  Maximillian A Rogers; Joshua D Hutcheson; Takehito Okui; Claudia Goettsch; Sasha A Singh; Arda Halu; Florian Schlotter; Hideyuki Higashi; Lixiang Wang; Mary C Whelan; Andrew K Mlynarchik; Alan Daugherty; Masatoshi Nomura; Masanori Aikawa; Elena Aikawa
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

9.  Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment.

Authors:  Livia Pisciotta; Antonella Bellocchio; Stefano Bertolini
Journal:  Lipids Health Dis       Date:  2012-09-22       Impact factor: 3.876

10.  Interaction of herbal compounds with biological targets: a case study with berberine.

Authors:  Xiao-Wu Chen; Yuan Ming Di; Jian Zhang; Zhi-Wei Zhou; Chun Guang Li; Shu-Feng Zhou
Journal:  ScientificWorldJournal       Date:  2012-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.